Chemistry:Α-Ethyl-N-methylphenethylamine
From HandWiki
 | |
| Clinical data | |
|---|---|
| Other names | N-Methyl-α-ethylphenethylamine; MEPEA; α-Et-N-Me-PEA; α-Et-MPEA; α-Et-NM-PEA; α-Et-Meth; α-Ethyl-methamphetamine; AENMPEA; AEMPEA; 2-Methylamino-1-phenylbutane; N-Methyl-1-phenyl-2-butanamine; PAL-426; PAL426 |
| Drug class | Norepinephrine–dopamine releasing agent; Stimulant; Sympathomimetic |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H17N |
| Molar mass | 163.264 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
α-Ethyl-N-methylphenethylamine (MEPEA; code name PAL-426) is a stimulant, designer drug, and norepinephrine–dopamine releasing agent (NDRA) of the phenethylamine, amphetamine, and phenylisobutylamine (α-ethylphenethylamine) families.[1][2][3][4][5][6] It is the N-methyl derivative of phenylisobutylamine (α-ethylphenethylamine; AEPEA) and is the α-ethyl homologue of methamphetamine (α-methyl-N-methylphenethylamine).[1][5][3][4]
The drug's EC50 values for induction of monoamine release are 58 nM for norepinephrine, 179 to 225 nM for dopamine, and 4,698 nM for serotonin.[1][2] Like amphetamine, MEPEA produces hyperlocomotion and sympathomimetic effects in rodents.[1] It is about one-tenth as potent as d-methamphetamine in drug discrimination and other tests in rodents.[5][3][4]
MEPEA was first described in the scientific literature by 1984.[5][6][4] It has been encountered as an ingredient in dietary supplements.[1]
See also
- N,α-Diethylphenethylamine
- α-Propylphenethylamine
- Buphedrone (α-ethyl-N-methylcathinone)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Amphetamine-like Neurochemical and Cardiovascular Effects of α-Ethylphenethylamine Analogs Found in Dietary Supplements". J Pharmacol Exp Ther 376 (1): 118–126. January 2021. doi:10.1124/jpet.120.000129. PMID 33082158.
- ↑ 2.0 2.1 "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett 5 (6): 623–627. June 2014. doi:10.1021/ml500113s. PMID 24944732.
- ↑ 3.0 3.1 3.2 "Structure-activity relationships of MDMA-like substances". NIDA Res Monogr 94: 1–29. 1989. PMID 2575223. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=150bf94a5ea3ed665dde3407a0ebbf3b9dbd8db9#page=12. "It seemed likely that an alpha-ethyl moiety would attenuate the ability of other phenethylamines to interact with dopaminergic systems. To test this hypothesis, the alpha-ethyl homolog of methamphetamine was synthesized. This compound (figure 7) was also tested in the drug discrimination paradigm in (+)-amphetamine trained rats, and compared with (+)-methamphetamine. While (+)-methamphetamine was found to have an ED50 of 1.90 micromoles per kilogram (µmol/kg), the racemic alpha-ethyl homolog only produced full substitution at high doses, and had an ED50 of 19.62 µmol/kg, making it approximately one-tenth the potency of (+)-methamphetamine. This confirmed our speculation, and illustrated that the alpha-ethyl group was effective in reducing the effect of phenethylamines on catecholamine pathways. [...] FIGURE 7. The alpha-ethyl homologue of methamphetamine [...]".
- ↑ 4.0 4.1 4.2 4.3 "Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Agents?". Annals of the New York Academy of Sciences. Topics in the Neurosciences. 600. Boston, MA: Springer US. 1990. pp. 105–131. doi:10.1007/978-1-4613-1485-1_7. ISBN 978-1-4612-8799-5. "Based on these data, it seemed likely that an alpha-ethyl moiety might attenuate the ability of other phenethylamines to interact with dopaminergic systems. To test this hypothesis, the alpha-ethyl homolog of methamphetamine (9, Figure 4) was synthesized. This compound (9) was also tested in the drug discrimination paradigm in (+)-amphetamine trained rats and compared with (+)-methamphetamine. The racemic alpha-ethyl homologue was found to possess approximately one-tenth the potency of (+)-methamphetamine. This supported the speculation that the alpha-ethyl group was generally effective in reducing the impact of phenethylamines on dopaminergic pathways."
- ↑ 5.0 5.1 5.2 5.3 "Medicinal Chemistry and Structure-Activity Relationships of Hallucinogens". Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives. New York: Raven Press. 1984. pp. 95–142. ISBN 978-0-89004-990-7. OCLC 10324237. https://bitnest.netfirms.com/external/Books/HallucinogensNBCP95. "Extension of the side-chain α-methyl to an ethyl group dramatically attenuates amphetamine-like activity. For example, the (+)-α-ethyl homolog 6 does not produce full substitution in rats trained to discriminate saline from 1 mg/kg (+)-amphetamine sulfate. Using the same paradigm, the racemic α-ethyl homolog of N-methylamphetamine (7) produced full substitution but had only about one-tenth the potency of amphetamine itself."
- ↑ 6.0 6.1 "Liquid chromatographic and mass spectral analysis of 1-(3,4-methylenedioxyphenyl)-3-butanamines, homologues of 3,4-methylenedioxyamphetamines". J Chromatogr Sci 27 (5): 240–243. May 1989. doi:10.1093/chromsci/27.5.240. PMID 2745665.
External links
 |  |
